People with HIV in Europe and Australia who switch to injectable treatment with cabotegravir / rilpivirine are just as likely to stay on their new regimen and maintain viral suppression as people taking oral treatment containing dolutegravir or bictegravir, a large international cohort study reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026) last week.
The findings come from one of the largest cohort studies to report on real-world use of the injectable regimen.
Previous cohort studies that reported on real-world use of cabotegravir / rilpivirine were either confined to one clinical centre or country, or lacked a comparator group.
Dr Alisa Timiryasova of the RESPOND HIV Cohort Collaboration looked at real-world outcomes of people who switched to cabotegravir / rilpivirine, comparing them to people who switched to dolutegravir- or bictegravir-based treatment.
The study was designed to measure discontinuation rates and virological and immunological outcomes 6, 12 and 18 months after switching.
The study identified 817 people who switched to cabotegravir / rilpivirine and 5426 who switched to dolutegravir or bictegravir in participating cohorts in Europe and Australia after January 2021. They were followed until the end of August 2024.
Those who switched to cabotegravir / rilpivirine were predominantly male (82%), had a median age of 48 years and were more frequently from southern Europe. They were more likely to be virally suppressed at the time of treatment switch (98%) than people taking dolutegravir or bictegravir (86%). People taking dolutegravir or bictegravir were slightly older (median age 52 years) and a larger proportion were female (28%).
A switch to cabotegravir / rilpivirine was more likely with each year that passed from the beginning of the study in 2021, reflecting greater availability of the combination and familiarity with its use. People in southern Europe were 78% more likely to switch to cabotegravir / rilpivirine than people in western Europe, and people in eastern Europe were 76% less likely to switch to it than people in western Europe.
The analysis measured two outcomes. The first was treatment discontinuation. Rates of treatment discontinuation were comparable: 12% of cabotegravir / rilpivirine switchers and 11% of dolutegravir or bictegravir switchers had discontinued their new regimen after 18 months. There was no difference in the frequency of discontinuation due to treatment failure but people taking cabotegravir / rilpivirine more often discontinued due to adverse events, including injection site reactions (44% vs 27% of discontinuations).
The second outcome, virological and immunological failure, also showed no difference between the two switch regimens. Three per cent of people switching to cabotegravir / rilpivirine and 5% of those switching to dolutegravir or bictegravir had at least one viral load measurement above 200 copies/ml, but just over two-thirds of those with isolated detectable viral load measurements in each group resuppressed viral load without changing treatment.
Among those who needed to change treatment, six out of 22 people in the cabotegravir / rilpivirine group developed treatment-associated resistance mutations during cabotegravir / rilpivirine treatment failure.
The RESPOND researchers concluded that their findings show that cabotegravir / rilpivirine offers an effective alternative to dolutegravir- or bictegravir-based treatment.